Listed

Chemed Corp: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on Apr 28, 2023 and accepted by EDGAR at Apr 28, 2023, 09:29 ET.

Share

Management's discussion and analysis

As filed, 29,940 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, Independent Contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little or no exposure related to customers, vendors, or employees in other regions of the world.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended March 31, 2023 2022
Service revenues and sales $560,157 $530,549
Net income $54,121 $64,169
Diluted EPS $3.58 $4.22
Adjusted net income $72,867 $72,780
Adjusted diluted EPS $4.82 $4.79
Adjusted EBITDA $111,033 $110,208
Adjusted EBITDA as a % of revenue 19.8% 20.8%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 27-28.

For the three months ended March 31, 2023, the increase in consolidated service revenues and sales was driven by a 7.9% increase at Roto-Rooter and a 3.8% increase at VITAS. The increase in service revenues at Roto-Rooter was driven mainly by an increase in plumbing, excavation, and water restoration. The increase in service revenues at VITAS is comprised primarily of a 3.0% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.9%, partially offset by 200-basis points as a result of CMS reimplementing the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020. Acuity mix shift had minimal impact in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes negatively impacted revenue growth by 10-basis points.

The pandemic has resulted in a significant shortage of licensed healthcare workers industry wide. VITAS has not been immune to this shortage. As a result, on July 1, 2022, VITAS implemented a hiring and retention bonus program for its licensed healthcare workers. It is a temporary program intended to help VITAS attract and retain licensed healthcare workers in light of the pandemic induced healthcare worker shortage. An eligible employee must continue in employment for a period of one-year from July 1st to receive a bonus. Additionally, employees hired between July 1, 2022 and June 30, 2023 are eligible if they continue employment for a one-year period from their hire date. The Company accrued $10.9 million in the first quarter of 2023 related to this retention bonus program. See page 29 for additional VITAS operating metrics.

While significant continuing issues related to the COVID-19 pandemic appear to be over or materially mitigated, we will continue to monitor any impact on our business including employees, customers, patients, and supply vendors.

While many companies have been adversely impacted by the banking crisis of March 2023, we do not anticipate any significant financial impact. The vast majority of our funds are in the two largest banks in the United States, as measured by total assets.

Management anticipates providing updated 2023 earnings guidance as part of the June 30, 2023, earnings press release.

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2023, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities includes an expansion feature that provides the Company the opportunity to increase its revolver and or term loan by an additional $250.0 million.

We made prepayments totaling $75.0 million in the first quarter of 2023, on the $100.0 million term loan. We plan to pay the remaining balance of $21.3 million on April 28, 2023. There are no prepayment penalties associated with this repayment. This will reduce the borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.

We have issued $45.3 million in standby letters of credit as of March 31, 2023, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of March 31, 2023, we have approximately $404.7 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2022 to March 31, 2023 include the following:

A $14.4 million increase in accounts receivable due to timing of receipts. See discussion below.

A $7.9 million decrease in prepaid income taxes due to timing of payments.

An $11.2 million increase in income tax due to timing of payments.

A $37.2 million decline in accrued compensation due to payment of 2022 bonuses in the first quarter of 2023.

An $8.3 million increase in other current liabilities due mainly to the healthcare worker retention bonus program at VITAS.

A $76.3 million decrease in long-term debt due to repayments.

Net cash provided by operating activities decreased $40.6 million from March 31, 2022 to March 31, 2023. The main drivers of the decrease are a decrease in net income of $10.0 million, and a $33.9 million increase in accounts receivable. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $42.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

Commitments and Contingencies

Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2023 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

Results of Operations

Three months ended March 31, 2023 versus 2022 - Consolidated Results

Our service revenues and sales for the first quarter of 2023 increased 5.6% versus services and sales revenues for the first quarter of 2022. Of this increase, an $18.3 million increase was attributable to Roto-Rooter, and an $11.3 million increase was attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Three months ended March 31, 2023 2022 Increase/(Decrease) Percent
Routine homecare $267,050 $257,636 3.7
Continuous care 19,941 19,578 1.9
General inpatient 29,093 26,570 9.5
Other 3,021 3,007 0.5
Subtotal 319,105 306,791 4.0
Medicare cap adjustment (2,750) (2,500) (10.0)
Room and board - net (2,769) (2,117) (30.8)
Implicit price concessions (3,108) (2,985) (4.1)
Net revenue $310,478 $299,189 3.8
Roto-Rooter
Drain cleaning $66,489 $66,687 (0.3)
Plumbing 50,453 47,672 5.8
Excavation 59,576 55,188 8.0
Other 193 165 17.0
Subtotal - short term core 176,711 169,712 4.1
Water restoration 50,762 40,360 25.8
Independent contractors 23,300 21,418 8.8
Outside franchisee fees 1,351 1,317 2.6
Other 4,745 4,191 13.2
Gross revenue 256,869 236,998 8.4
Implicit price concessions (7,190) (5,638) (27.5)
Net revenue 249,679 231,360 7.9
Total Revenues $560,157 $530,549 5.6

Days of care at VITAS during the quarters were as follows:

Three months ended March 31, 2023 2022 Increase/(Decrease) Percent
Routine homecare 1,286,437 1,258,672 2.2
Nursing home 265,429 248,468 6.8
Respite 5,760 5,368 7.3
Subtotal routine homecare and respite 1,557,626 1,512,508 3.0
General inpatient 26,369 24,587 7.2
Continuous care 20,686 21,082 (1.9)
Total days of care 1,604,681 1,558,177 3.0

The increase in service revenues at VITAS is comprised primarily of a 3.0% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.9%, partially offset by 200-basis points as a result of CMS reimplementing the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020. Acuity mix shift had minimal impact in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes negatively impacted revenue growth by 10-basis points.

The increase in plumbing revenues for the first quarter of 2023 versus 2022 is attributable to a 13.0% increase in price and service mix shift offset by a 7.2% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, the 8.0% increase in excavation revenue and the 25.8% increase in water restoration revenue are mainly a function of the numbers and size of drain cleaning issues we encounter on a quarterly basis. Independent Contractor revenue increased 8.8% due mainly to increased expansion into water restoration.

The consolidated gross margin was 33.8% in the first quarter of 2023 as compared with 36.6% in the first quarter of 2022. On a segment basis, VITAS’ gross margin was 18.3% in the first quarter of 2023 as compared with 24.0%, in the first quarter of 2022. The decrease in gross margin at VITAS is mostly the result of the $10.9 million expense recorded in the first quarter of 2023 for the licensed healthcare worker retention bonus program. The Roto-Rooter segment’s gross margin was 53.1% for the first quarter of 2023 as compared with 52.8% in the first quarter of 2022.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended March 31, 2023 2022
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $97,902 $92,578
Impact of market value adjustments related to assets held in deferred compensation trusts (321) (3,934)
Long-term incentive compensation 2,514 1,310
Total SG&A expenses $100,095 $89,954

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2023 were up 5.8% when compared to the first quarter of 2022. This increase was mainly a result of variable selling and general administrative expenses and overall inflation-related cost increases, including salary at both operating units.

Other (expense)/income – net comprise (in thousands):

Three months ended March 31, 2023 2022
Market value adjustment on assets held in deferred compensation trusts $(321) $(3,934)
Interest income 150 73
Other 68 (1)
Total expense - net $(103) $(3,862)

Our effective tax rate reconciliation is as follows (in thousands):

Three months ended March 31, 2023 2022
Income tax provision calculated at the statutory federal rate $14,945 $17,787
Stock compensation tax benefits (1,650) (1,441)
State and local income taxes 2,940 3,241
Other--net 809 946
Income tax provision $17,044 $20,533
Effective tax rate 23.9% 24.2%

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

VITAS Three months ended March 31, 2023 2022
Licensed healthcare worker retention bonus $(8,144) $-
Direct costs related to COVID-19 - (292)
Roto-Rooter
Amortization of reacquired franchise agreements (1,729) (1,729)
Litigation settlements (1,290) -
Direct costs related to COVID-19 - (706)
Corporate
Stock option expense (7,010) (6,166)
Long-term incentive compensation (2,223) (1,159)
Excess tax benefits on stock compensation 1,650 1,441
Total $(18,746) $(8,611)

Three months ended March 31, 2023 versus 2022 - Segment Results

Net income/(loss) for the first quarter of 2023 versus the first quarter of 2022 by segment (in thousands):

Three months ended March 31, 2023 2022
VITAS $24,764 $36,481
Roto-Rooter 47,653 43,937
Corporate (18,296) (16,249)
$54,121 $64,169

VITAS’ after-tax earnings decreased primarily due to the $8.1 million in after-tax expense related to VITAS’ licensed healthcare worker retention bonus program, as well as the reimplementation of the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020, in the first quarter of 2023 when compared to the first quarter of 2022. After-tax earnings as a percent of revenue at VITAS in the first quarter of 2023 was 8.0% as compared to 12.2% in the first quarter of 2022.

Roto-Rooter’s net income was impacted in the first quarter of 2023 compared to the first quarter of 2022 primarily by higher revenue. After-tax earnings as a percent of revenue at Roto-Rooter in the first quarter of 2023 was 19.1%, as compared to 19.0% in the first quarter of 2022.

After-tax Corporate expenses for the first quarter of 2023 increased 12.6% when compared to 2022 due to a $1.9 million increase in stock-based compensation.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(in thousands)(unaudited)

2023 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $310,478 $249,679 $- $560,157
Cost of services provided and goods sold 253,654 117,051 - 370,705
Selling, general and administrative expenses 23,336 60,813 15,946 100,095
Depreciation 4,958 7,312 16 12,286
Amortization 26 2,487 - 2,513
Other operating expense 12 1,727 - 1,739
Total costs and expenses 281,986 189,390 15,962 487,338
Income/(loss) from operations 28,492 60,289 (15,962) 72,819
Interest expense (50) (133) (1,368) (1,551)
Intercompany interest income/(expense) 4,648 2,743 (7,391) -
Other (expense)/ income—net 189 29 (321) (103)
Income/(expense) before income taxes 33,279 62,928 (25,042) 71,165
Income taxes (8,515) (15,275) 6,746 (17,044)
Net income/(loss) $24,764 $47,653 $(18,296) $54,121
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Licensed healthcare worker retention bonus $(10,916) $- $- $(10,916)
Stock option expense - - (8,482) (8,482)
Long-term incentive compensation - - (2,514) (2,514)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Litigation settlements - (1,756) - (1,756)
Total $(10,916) $(4,108) $(10,996) $(26,020)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Licensed healthcare worker retention bonus $(8,144) $- $- $(8,144)
Stock option expense - - (7,010) (7,010)
Long-term incentive compensation - - (2,223) (2,223)
Amortization of reacquired franchise agreements - (1,729) - (1,729)
Litigation settlements - (1,290) - (1,290)
Excess tax benefits on stock compensation - - 1,650 1,650
Total $(8,144) $(3,019) $(7,583) $(18,746)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2022

(in thousands)(unaudited)

2022 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $299,189 $231,360 $- $530,549
Cost of services provided and goods sold 227,240 109,312 - 336,552
Selling, general and administrative expenses 22,453 56,954 10,547 89,954
Depreciation 5,551 6,569 18 12,138
Amortization 24 2,494 - 2,518
Other operating expense/(income) (148) 161 - 13
Total costs and expenses 255,120 175,490 10,565 441,175
Income/(loss) from operations 44,069 55,870 (10,565) 89,374
Interest expense (52) (115) (643) (810)
Intercompany interest income/(expense) 4,656 2,176 (6,832) -
Other (expense)/income—net 37 35 (3,934) (3,862)
Income/(expense) before income taxes 48,710 57,966 (21,974) 84,702
Income taxes (12,229) (14,029) 5,725 (20,533)
Net income/(loss) $36,481 $43,937 $(16,249) $64,169
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $$ (7,451) $(7,451)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Direct costs related to COVID-19 (391) (961) - (1,352)
Long-term incentive compensation - - (1,310) (1,310)
Total $(391) $(3,313) $(8,761) $(12,465)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(6,166) $(6,166)
Amortization of reacquired franchise agreements - (1,729) - (1,729)
Long-term incentive compensation - - (1,159) (1,159)
Direct costs related to COVID-19 (292) (706) - (998)
Excess tax benefits on stock compensation - - 1,441 1,441
Total $(292) $(2,435) $(5,884) $(8,611)

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2023 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $24,764 $47,653 $(18,296) $54,121
Add/(deduct):
Interest expense 50 133 1,368 1,551
Income taxes 8,515 15,275 (6,746) 17,044
Depreciation 4,958 7,312 16 12,286
Amortization 26 2,487 - 2,513
EBITDA 38,313 72,860 (23,658) 87,515
Add/(deduct):
Intercompany interest expense/(income) (4,648) (2,743) 7,391 -
Interest income (121) (29) - (150)
Licensed healthcare retention bonus 10,916 - - 10,916
Stock option expense - - 8,482 8,482
Long-term incentive compensation - - 2,514 2,514
Litigation settlements - 1,756 - 1,756
Adjusted EBITDA $44,460 $71,844 $(5,271) $111,033
Chemed
For the three months ended March 31, 2022 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $36,481 $43,937 $(16,249) $64,169
Add/(deduct):
Interest expense 52 115 643 810
Income taxes 12,229 14,029 (5,725) 20,533
Depreciation 5,551 6,569 18 12,138
Amortization 24 2,494 - 2,518
EBITDA 54,337 67,144 (21,313) 100,168
Add/(deduct):
Intercompany interest expense/(income) (4,656) (2,176) 6,832 -
Interest income (37) (36) - (73)
Stock option expense - - 7,451 7,451
Direct costs related to COVID-19 391 961 - 1,352
Long-term incentive compensation - - 1,310 1,310
Adjusted EBITDA $50,035 $65,893 $(5,720) $110,208

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended March 31, 2023 2022
Net income as reported $54,121 $64,169
Add/(deduct) pre-tax cost of:
Licensed healthcare worker retention bonus 10,916 -
Stock option expense 8,482 7,451
Long-term incentive compensation 2,514 1,310
Amortization of reacquired franchise agreements 2,352 2,352
Litigation settlements 1,756 -
Direct costs related to COVID-19 - 1,352
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (5,624) (2,413)
Excess tax benefits on stock compensation (1,650) (1,441)
Adjusted net income $72,867 $72,780
Diluted Earnings Per Share As Reported
Net income $3.58 $4.22
Average number of shares outstanding 15,110 15,192
Adjusted Diluted Earnings Per Share
Adjusted net income $4.82 $4.79
Adjusted average number of shares outstanding 15,110 15,192
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

OPERATING STATISTICS Net revenue ($000) Three Months Ended March 31, 2023 2022
Homecare $267,050 $257,636
Inpatient 29,093 26,570
Continuous care 19,941 19,578
Other 3,021 3,007
Subtotal $319,105 $306,791
Room and board, net (2,769) (2,117)
Contractual allowances (3,108) (2,985)
Medicare cap allowance (2,750) (2,500)
Total $310,478 $299,189
Net revenue as a percent of total before Medicare cap allowances
Homecare 83.7% 84.0%
Inpatient 9.1 8.7
Continuous care 6.2 6.4
Other 1.0 0.9
Subtotal 100.0 100.0
Room and board, net (0.8) (0.7)
Contractual allowances (1.0) (1.0)
Medicare cap allowance (0.9) (0.8)
Total 97.3% 97.5%
Days of care
Homecare 1,286,437 1,258,672
Nursing home 265,429 248,468
Respite 5,760 5,368
Subtotal routine homecare and respite 1,557,626 1,512,508
Inpatient 26,369 24,587
Continuous care 20,686 21,082
Total 1,604,681 1,558,177
Number of days in relevant time period 90 90
Average daily census (days)
Homecare 14,294 13,985
Nursing home 2,949 2,761
Respite 64 60
Subtotal routine homecare and respite 17,307 16,806
Inpatient 293 273
Continuous care 230 234
Total 17,830 17,313
Total Admissions 16,179 16,530
Total Discharges 15,405 16,862
Average length of stay (days) 99.9 104.8
Median length of stay (days) 15.0 14.0
ADC by major diagnosis
Cerebro 41.8% 36.7%
Neurological 19.3 22.9
Cancer 10.5 11.1
Cardio 16.0 15.9
Respiratory 7.3 7.4
Other 5.1 6.0
Total 100.0% 100.0%
Admissions by major diagnosis
Cerebro 26.4 22.9%
Neurological 10.7 12.9
Cancer 24.7 24.9
Cardio 16.2 14.1
Respiratory 10.9 11.1
Other 11.1 14.1
Total 100.0% 100.0%
Estimated uncollectible accounts as a percent of revenues 1.0% 1.0%
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 34.7 33.6
Days of revenue outstanding- including unapplied Medicare payments 29.2 23.9

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Market risk

As filed, 586 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2023, the Company had $21.3 million of variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Controls and procedures

As filed, 900 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 141 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$310.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-01-01 to 2023-03-31$370.7mus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2023-01-01 to 2023-03-31$100.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-01-01 to 2023-03-31$72.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-01-01 to 2023-03-31$1.6mus-gaap:InterestExpense
Income tax3 months2023-01-01 to 2023-03-31$17.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-01-01 to 2023-03-31$54.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-01-01 to 2023-03-31$3.58us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-01-01 to 2023-03-31$3.62us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-01-01 to 2023-03-3115,110,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-01-01 to 2023-03-31$60.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$17.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2023-01-01 to 2023-03-31$5.7mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2023-03-31$58.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-03-31$262.2mus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$1.43bnus-gaap:Assets
Current liabilitiesAt period end2023-03-31$283.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-03-31$551.1mus-gaap:Liabilities
Long-term debtAt period end2023-03-31$16.3mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-03-31$5.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2023-03-31$880.1mus-gaap:StockholdersEquity
Shares outstandingAt period end2023-03-3115,019,778 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001562762-23-000183. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.